Executive at Gene Therapy Developer Sells Portion of Shares According to Pre-Established Plan

uniQure N.V. (NASDAQ: QURE) insider Jack Kaye exercised options on January 9 to acquire 6,390 common shares, which he immediately sold at an average price of $27.28 per share. Following this transaction, Kaye’s direct holdings decreased to approximately 20,643 shares, with a remaining stake valued at roughly $558,000 (about KRW 730 million). The trades were conducted under a Rule 10b5-1 prearranged trading plan adopted in June 2025.

uniQure also announced that it has scheduled a Type A meeting with the U.S. Food and Drug Administration on January 9 as it advances the regulatory timeline and commercialization preparations for its Huntington’s disease gene therapy candidate, AMT-130. In the second half of 2025, the company strengthened its financial flexibility by securing up to $175 million in non-dilutive funding—approximately KRW 230 billion—through a major public offering and debt refinancing.

Headquartered in both the Netherlands and the United States, uniQure is a gene therapy specialist that, building on its success in gaining approval for a hemophilia B treatment, is developing a pipeline addressing serious conditions such as Huntington’s disease, refractory temporal lobe epilepsy, ALS, and Fabry disease. In recent years, the company has established a long-term financing structure to support R&D and potential commercialization costs by combining asset sales, equity offerings, and loan refinancings.